|
[1]
|
Haberland, M., Montgomery, R.L. and Olson, E.N. (2009) The Many Roles of Histone Deacetylases in Development and Physiology: Implications for Disease and Therapy. Nature Reviews Genetics, 10, 32-42. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Bassett, S.A. and Barnett, M.P.G. (2014) The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease. Nutrients, 6, 4273-4301. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Villagra, A., et al. (2009) The Histone Deacetylase HDAC11 Regulates the Expression of Interleukin 10 and Immune Tolerance. Nature Immunology, 10, 92-100.
https://pubmed.ncbi.nlm.nih.gov/19011628/
|
|
[4]
|
Witt, O., Deubzer, H.E., Milde, T. and Oehme, I. (2009) HDAC Family: What Are the Cancer Relevant Targets? Cancer Letters, 277, 8-21. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Das, V., Kalyan, G., Hazra, S. and Pal, M. (2018) Understanding the Role of Structural Integrity and Differential Expression of Integrin Profiling to Identify Potential Therapeutic Targets in Breast Cancer. Journal of Cellular Physiology, 233, 168-185. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33.
https://pubmed.ncbi.nlm.nih.gov/35020204
|
|
[7]
|
Li, Y.H., et al. (2018) Expression Patterns of E2F Transcription Factors and Their Potential Prognostic Roles in Breast Cancer. Oncology Letters, 15, 9216-9230.
https://pubmed.ncbi.nlm.nih.gov/29844824
|
|
[8]
|
Zucchetti, B., Shimada, A.K., Katz, A. and Curigliano, G. (2019) The Role of Histone Deacetylase Inhibitors in Metastatic Breast Cancer. Breast, 43, 130-134.
https://pubmed.ncbi.nlm.nih.gov/30553187/
|
|
[9]
|
Maccallini, C., et al. (2022) HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer. Pharmaceuticals (Basel), 15, Article No. 667.
https://pubmed.ncbi.nlm.nih.gov/35745586/
|
|
[10]
|
Ramaiah, M.J., Tangutur, A.D. and Manyam, R.R. (2021) Epi-genetic Modulation and Understanding of HDAC Inhibitors in Cancer Therapy. Life Sciences, 277, Article ID: 119504. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Zhang, Z., et al. (2005) Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast. Breast Cancer Research and Treatment, 94, 11-16. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
吴文梅, 李华琴, 黄源, 等. HDAC1 (Rpd3)在疾病中的功能研究进展[J]. 分子诊断与治疗杂志, 2021, 13(6): 849-852.
|
|
[13]
|
Shetty, M.G., et al. (2021) Histone Deacetylase 2 Selec-tive Inhibitors: A Versatile Therapeutic Strategy as Next Generation Drug Target in Cancer Therapy. Pharmacological Research, 170, Article ID: 105695.
https://pubmed.ncbi.nlm.nih.gov/34082029/
|
|
[14]
|
Müller, B.M., et al. (2013) Differential Expression of Histone Deacetylases HDAC1, 2 and 3 in Human Breast Cancer—Overexpression of HDAC2 and HDAC3 Is Associated with Clinicopathological Indicators of Disease Progression. BMC Cancer, 13, Article No. 215. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Wen, Y.D., et al. (2000) The Histone Deacetylase-3 Complex Contains Nuclear Receptor Corepressors. Proceedings of the National Academy of Sciences of the United States of Amer-ica, 97, 7202-7207.
https://pubmed.ncbi.nlm.nih.gov/10860984/
|
|
[16]
|
Khochbin, S., Verdel, A., Lemercier, C. and Seigneurin-Berny, D. (2001) Functional Significance of Histone Deacetylase Diversity. Current Opinion in Genetics and Development, 11, 162-166. [Google Scholar] [CrossRef]
|
|
[17]
|
Zhang, Z., et al. (2004) HDAC6 Expression Is Correlated with Better Survival in Breast Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10, 6962-6968. [Google Scholar] [CrossRef]
|
|
[18]
|
Hrzenjak, A., et al. (2006) Valproate Inhibition of Histone Deacetylase 2 Affects Differentiation and Decreases Proliferation of Endometrial Stromal Sarcoma Cells. Molecular Cancer Therapeutics, 5, 2203-2210. [Google Scholar] [CrossRef]
|
|
[19]
|
Zhang, C., Richon, V., Ni, X., Talpur, R. and Duvic, M. (2005) Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action. Journal of Investigative Dermatology, 125, 1045-1052. [Google Scholar] [CrossRef]
|
|
[20]
|
Ho, M., et al. (2020) Targeting Histone Deacetylase 3 (HDAC3) in the Bone Marrow Microenvironment Inhibits Multiple Myeloma Proliferation by Modulating Exosomes and IL-6 Trans-Signaling. Leukemia, 34, 196-209. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Wawruszak, A., et al. (2021) Vorinostat (SAHA) and Breast Cancer: An Overview. Cancers, 13, Article No. 4700. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Booth, L., et al. (2017) HDAC Inhibitors Enhance the Immunother-apy Response of Melanoma Cells. Oncotarget, 8, 83155-83170.
https://pubmed.ncbi.nlm.nih.gov/29137331/
|
|
[23]
|
Terranova-Barberio, M., et al. (2017) HDAC Inhibition Potenti-ates Immunotherapy in Triple Negative Breast Cancer. Oncotarget, 8, 114156-114172.
https://pubmed.ncbi.nlm.nih.gov/29371976/
|
|
[24]
|
Levine, A.J. (1997) p53, the Cellular Gatekeeper for Growth and Division. Cell, 88, 323-331. [Google Scholar] [CrossRef]
|
|
[25]
|
Luo, J., Su, F., Chen, D., Shiloh, A. and Gu, W. (2000) Deacetylation of p53 Modulates Its Effect on Cell Growth and Apoptosis. Nature, 408, 377-381. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Xu, W.S., Parmigiani, R.B. and Marks, P.A. (2007) Histone Deacetylase Inhibitors: Molecular Mechanisms of Action. Oncogene, 26, 5541-5552. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Yang, X., et al. (2001) Synergistic Activation of Functional Estrogen Receptor (ER)-alpha by DNA Methyltransferase and Histone Deacetylase Inhibition in Human ER-Alpha-Negative Breast Cancer Cells. Cancer Research, 61, 7025-7029.
|
|
[28]
|
McMahon, M., et al. (2014) HDAC Inhibitors Increase NRF2-Signaling in Tumour Cells and Blunt the Efficacy of Co-Adminstered Cytotoxic Agents. PLOS ONE, 9, e114055.
https://pubmed.ncbi.nlm.nih.gov/25427220/
|
|
[29]
|
Teng, Y., Liu, M. and Cowell, J.K. (2011) Functional Interrela-tionship between the WASF3 and KISS1 Metastasis-Associated Genes in Breast Cancer Cells. International Journal of Cancer, 129, 2825-2835. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Fares, J., et al. (2020) Molecular Principles of Metastasis: A Hallmark of Cancer Revisited. Signal Transduction and Targeted Therapy, 5, 28.
https://pubmed.ncbi.nlm.nih.gov/32296047/
|
|
[31]
|
Gallagher, S.J., et al. (2018) HDAC Inhibitors Restore BRAF-Inhibitor Sensitivity by Altering PI3K and Survival Signalling in a Subset of Melanoma. International Journal of Cancer, 142, 1926-1937. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Elmore, S. (2007) Apoptosis: A Review of Pro-grammed Cell Death. Toxicologic Pathology, 35, 495-516.
https://pubmed.ncbi.nlm.nih.gov/17562483/
|
|
[33]
|
Yu, Z., Zhang, W. and Kone, B.C. (2002) Histone Deacetylases Augment Cytokine Induction of the iNOS Gene. Journal of the American Society of Nephrology, 13, 2009-2017. [Google Scholar] [CrossRef]
|
|
[34]
|
Li, Y. and Seto, E. (2016) HDACs and HDAC Inhib-itors in Cancer Development and Therapy. Cold Spring Harbor Perspectives in Medicine, 6, a026831. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Chen, S.Y. and Sang, N.L. (2011) Histone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia-Inducible Factors. Journal of Biomedicine and Biotechnology, 2011, Article ID: 197946.
https://pubmed.ncbi.nlm.nih.gov/21151670/
|
|
[36]
|
Kim, H.-J. and Bae, S.-C. (2011) Histone Deacetylase Inhibitors: Molecular Mechanisms of Action and Clinical Trials as Anti-Cancer Drugs. American Journal of Translational Research, 3, 166-179.
|
|
[37]
|
Chang, X., et al. (2005) 3,3’-Diindolylmethane Inhibits Angiogenesis and the Growth of Transplanta-ble Human Breast Carcinoma in Athymic Mice. Carcinogenesis, 26, 771-778. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Lee, J.-H., Choy, M.L., Ngo, L., Foster, S.S. and Marks, P.A. (2010) Histone Deacetylase Inhibitor Induces DNA Damage, Which Normal but Not Transformed Cells Can Repair. Proceed-ings of the National Academy of Sciences of the United States of America, 107, 14639-14644.
https://pubmed.ncbi.nlm.nih.gov/20679231/
|
|
[39]
|
Zhu, P., et al. (2004) Induction of HDAC2 Expression upon Loss of APC in Colorectal Tumorigenesis. Cancer Cell, 5, 455-463. [Google Scholar] [CrossRef]
|
|
[40]
|
Brehm, A., et al. (1998) Retinoblastoma Protein Recruits Histone Deacetylase to Repress Transcription. Nature, 391, 597-601. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Zhang, X.H., et al. (2007) HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin. Molecular Cell, 27, 197-213.
https://pubmed.ncbi.nlm.nih.gov/17643370/
|
|
[42]
|
Li, X., et al. (2017) Placental Growth Factor Contrib-utes to Liver Inflammation, Angiogenesis, Fibrosis in Mice by Promoting Hepatic Macrophage Recruitment and Activa-tion. Frontiers in Immunology, 8, Article No. 801.
https://pubmed.ncbi.nlm.nih.gov/28744285/
|
|
[43]
|
Yang, W., Liu, Y., Gao, R., Yu, H. and Sun, T. (2018) HDAC6 Inhibition Induces Glioma Stem Cells Differentiation and Enhances Cellular Radiation Sensitivity through the SHH/Gli1 Signaling Pathway. Cancer Letters, 415, 164-176. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Huang, H.B., et al. (2012) HDAC Inhibitor L-Carnitine and Pro-teasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity in Vitro and in Vivo. PLOS ONE, 7, e52576.
https://pubmed.ncbi.nlm.nih.gov/23285100/
|
|
[45]
|
Pan, L.N., Lu, J. and Huang, B.Q. (2007) HDAC Inhibitors: A Potential New Category of Anti-Tumor Agents. Cellular & Molecular Immunology, 4, 337-343.
https://pubmed.ncbi.nlm.nih.gov/17976313/
|
|
[46]
|
Maiti, A., Qi, Q.Y., Peng, X., Yan, L., Takabe, K. and Hait, N.C. (2019) Class I Histone Deacetylase Inhibitor Suppresses Vasculogenic Mimicry by Enhancing the Expression of Tumor Suppressor and Anti-Angiogenesis Genes in Aggressive Human TNBC Cells. International Journal of Oncology, 55, 116-130.
https://pubmed.ncbi.nlm.nih.gov/31059004/
|
|
[47]
|
McClure, J.J., Li, X. and Chou, C.J. (2018) Advances and Chal-lenges of HDAC Inhibitors in Cancer Therapeutics. Advances in Cancer Research, 138, 183-211. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Ma, X., Ezzeldin, H.H. and Diasio, R.B. (2009) Histone Deacety-lase Inhibitors: Current Status and Overview of Recent Clinical Trials. Drugs, 69, 1911-1934. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Sun, Y., Sun, Y., Yue, S., Wang, Y. and Lu, F. (2018) Histone Deacetylase Inhibitors in Cancer Therapy. Current Topics in Medicinal Chemistry, 18, 2420-2428. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Ozaki, K., et al. (2008) Histone Deacetylase Inhibitors Enhance the Chemosensitivity of Tumor Cells with Cross-Resistance to a Wide Range of DNA-Damaging Drugs. Can-cer Science, .99, 376-384. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Zucchetti, B., Shimada, A.K., Katz, A. and Curigliano, G. (2019) The Role of Histone Deacetylase Inhibitors in Metastatic Breast Cancer. Breast (Edinburgh, Scotland), 43, 130-134. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Chen, S.-Y., et al. (2016) Histone Deacetylase Inhibitor Reverses Multidrug Resistance by Attenuating the Nucleophosmin Level through PI3K/Akt Pathway in Breast Cancer. International Journal of Oncology, 49, 294-304.
https://pubmed.ncbi.nlm.nih.gov/27211281/
|
|
[53]
|
Shustov, A., et al. (2017) Romidepsin Is Effective and Well Tol-erated in Older Patients with Peripheral T-Cell Lymphoma: Analysis of Two Phase II Trials. Leukemia & Lymphoma, 58, 2335-2341. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Feng, W., Cai, D., Zhang, B., Lou, G. and Zou, X. (2015) Combination of HDAC Inhibitor TSA and Silibinin Induces Cell Cycle Arrest and Apoptosis by Targeting Survivin and cyclinB1/Cdk1 in Pancreatic Cancer Cells. Biomedicine & Pharmacotherapy, 74, 257-264. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Wang, D.G., et al. (2013) Inhibitory Effect of Valproic Acid on Bladder Cancer in Combination with Chemotherapeutic Agents in Vitro and in Vivo. Oncology Letters, 6, 1492-1498.
https://pubmed.ncbi.nlm.nih.gov/24179547/
|
|
[56]
|
Lakshmaiah, K.C., Jacob, L.A., Aparna, S., Lokanatha, D. and Saldanha, S.C. (2014) Epigenetic Therapy of Cancer with Histone Deacetylase Inhibitors. Journal of Cancer Research and Therapeutics, 10, 469-478. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Zheng, H., et al. (2016) HDAC Inhibitors Enhance T-Cell Chemo-kine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research, 22, 4119-4132.
https://pubmed.ncbi.nlm.nih.gov/26964571/
|
|
[58]
|
Woods, D.M, et al. (2015) HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunology Research, 3, 1375-1385.
https://pubmed.ncbi.nlm.nih.gov/26297712/
|
|
[59]
|
Marks, P.A. and Breslow, R. (2007) Dimethyl Sulfoxide to Vo-rinostat: Development of This Histone Deacetylase Inhibitor as an Anticancer Drug. Nature Biotechnology, 25, 84-90. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
West, A.C. and Johnstone, R.W. (2014) New and Emerging HDAC Inhibi-tors for Cancer Treatment. Journal of Clinical Investigation, 124, 30-39. [Google Scholar] [CrossRef]
|
|
[61]
|
Kelly, W.K., et al. (2005) Phase I Study of an Oral Histone Deacetylase In-hibitor, Suberoylanilide Hydroxamic Acid, in Patients with Advanced Cancer. Journal of Clinical Oncology, 23, 3923-3931. [Google Scholar] [CrossRef]
|
|
[62]
|
Fuino, L., et al. (2003) Histone Deacetylase Inhibitor LAQ824 Down-Regulates Her-2 and Sensitizes Human Breast Cancer Cells to Trastuzumab, Taxotere, Gemcitabine, and Epothi-lone B. Molecular Cancer Therapeutics, 2, 971-984.
|
|
[63]
|
Bolden, J.E., Peart, M.J. and Johnstone, R.W. (2006) Anti-cancer Activities of Histone Deacetylase Inhibitors. Nature Reviews Drug Discovery, 5, 769-784. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Foss, F., et al. (2016) Romidepsin for the Treatment of Relapsed/Refractory Peripheral T Cell Lymphoma: Prolonged Stable Disease Provides Clinical Benefits for Patients in the Pivotal Trial. Jour-nal of Hematology Oncology, 9, Article No. 22.
https://pubmed.ncbi.nlm.nih.gov/26965915/
|